Article ; Online: Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS.
2023 Volume 26, Issue 1, Page(s) 463–472
Abstract: Introduction and aim: Dalbavancin is an antibiotic with activity against gram-positive bacteria that allows early discharge of patients requiring intravenous therapy. Outpatient treatment helps offset hospitalisation costs associated with standard ... ...
| Abstract | Introduction and aim: Dalbavancin is an antibiotic with activity against gram-positive bacteria that allows early discharge of patients requiring intravenous therapy. Outpatient treatment helps offset hospitalisation costs associated with standard intravenous treatment. Our objective was to assess the cost of disease management, including treatment with dalbavancin, in a Spanish hospital for 1 year, and the hypothetical costs associated with treatment with other therapeutic alternatives to dalbavancin. Methods: A single-centre, observational, retrospective post-hoc analysis was conducted based on electronic medical records analysing all patients who received dalbavancin treatment throughout 1 year; cost analysis was performed for the whole process. In addition, three scenarios designed on the basis of real clinical practice by clinical experts were hypothesised: (i) individual therapeutic alternative to dalbavancin, (ii) all patients treated with daptomycin, and (iii) all days of dalbavancin as outpatient treatment transformed into hospital stay. Costs were obtained from the hospital. Results: Thirty-four patients were treated with dalbavancin; their mean age was 57.9 years, and 70.6% were men. The main reasons for dalbavancin use were outpatient management (61.7%, Main limitation: Limited sample size obtained from a single centre. Conclusion: The economic impact of the management of these infections is high. The cost of dalbavancin is offset by the decreased length of stay. |
|---|---|
| MeSH term(s) | Male ; Humans ; Middle Aged ; Female ; Retrospective Studies ; Teicoplanin/therapeutic use ; Teicoplanin/adverse effects ; Anti-Bacterial Agents ; Costs and Cost Analysis ; Hospitals |
| Chemical Substances | dalbavancin (808UI9MS5K) ; Teicoplanin (61036-62-2) ; Anti-Bacterial Agents |
| Language | English |
| Publishing date | 2023-03-23 |
| Publishing country | England |
| Document type | Journal Article |
| ZDB-ID | 2270945-9 |
| ISSN | 1941-837X ; 1369-6998 |
| ISSN (online) | 1941-837X |
| ISSN | 1369-6998 |
| DOI | 10.1080/13696998.2023.2190704 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6450: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.